Skip to main content

Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS), Milestone Pharmaceuticals (MIST) and Astria Therapeutics (ATXS)

Tipranks - Tipranks - Fri Nov 14, 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Codexis (CDXS – Research Report), Milestone Pharmaceuticals (MIST – Research Report) and Astria Therapeutics (ATXS – Research Report).

Meet Your ETF AI Analyst

Codexis (CDXS)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Codexis today. The company’s shares closed last Thursday at $1.90.

According to TipRanks.com, Hewitt is a 2-star analyst with an average return of 0.7% and a 45.1% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Clover Health Investments, and Dyadic International. ;'>

Currently, the analyst consensus on Codexis is a Moderate Buy with an average price target of $6.00, representing a 210.9% upside. In a report issued on November 6, Cantor Fitzgerald also maintained a Buy rating on the stock with a $11.00 price target.

See the top stocks recommended by analysts >>

Milestone Pharmaceuticals (MIST)

TD Cowen analyst Ritu Baral maintained a Hold rating on Milestone Pharmaceuticals today. The company’s shares closed last Thursday at $1.91.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.9% and a 56.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Sionna Therapeutics, Inc. ;'>

Milestone Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.

Astria Therapeutics (ATXS)

In a report released today, Jeff Jones from Oppenheimer maintained a Hold rating on Astria Therapeutics. The company’s shares closed last Thursday at $12.48.

According to TipRanks.com, Jones is a 3-star analyst with an average return of 3.4% and a 42.2% success rate. Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Corbus Pharmaceuticals, and Chemomab Therapeutics. ;'>

Astria Therapeutics has an analyst consensus of Hold, with a price target consensus of $20.00, a 59.4% upside from current levels. In a report released yesterday, Cantor Fitzgerald also downgraded the stock to Hold.

Read More on CDXS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).